Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.

Front Immunol · 2019 · PMC6688426 · PMID 31428099

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

Moreover, a comparison of CXCR4 expression score between diagnostic (2.8 ± 2.1) and relapsed/refractory (5.1 ± 2.9)specimens revealed a significant trend toward higher levels of CXCR4 expression in relapse samples than in diagnostic samples ( Figure 1D ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.